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OBJECTIVES The study investigated the expression and relationship of deoxyribonucleic acid (DNA) repair
enzymes with hemodynamic and nitric oxide (NO)-mediated stress in the failing myocar-
dium.
BACKGROUND The role of apoptosis in human heart failure is controversial. Experimental studies suggested
that NO-mediated stress modulates apoptosis of the cardiac myocytes. Of note, DNA repair
enzymes such as redox factor/apurinic/apyridimine endonuclease Ref-1 protein, proliferative
cell nuclear antigen (PCNA), the poly (ADP-ribose) polymerase (PARP), and DNA-protein
kinase (DNA-PK) determine the cell fate after the DNA damage.
METHODS Left ventricular (LV) endomyocardial biopsies from 23 patients with dilated cardiomyopathy
were analyzed by immunohistochemistry.
RESULTS Terminal deoxynucleotidyltransferase-mediated biotin-dUTP nick-end labeling (TUNEL)
or cleaved caspase-3 and cleaved PARP could not be detected. The number of Ref-1-positive
myocytes tended to be higher in patients with LV ejection fraction (EF)35% versus LV EF
35% (21.23  4.8% vs. 13.8  5.8%, p  0.1). The PCNA (7.1  2.8% vs. 0.9  0.6%,
p  0.05) and DNA-PK expressions (39.5  5.4% vs. 8.6  5.5%, p  0.01) were higher
in patients with LVEF 35% vs. LVEF 35%. The PCNA, Ref-1, and DNA-PK
expression correlated with the LV end-systolic wall stress (r  0.61, p  0.01; r  0.52, p
 0.01; and r  0.73, p  0.001, respectively). In addition, the PCNA and DNA-PK
expression correlated with inducible NO synthase (r  0.41, p  0.05, and r  0.53, p 
0.01, respectively).
CONCLUSIONS In this study, apoptosis could not be detected in the failing myocardium owing to idiopathic
dilated cardiomyopathy. In contrast, failing myocardium was characterized by active DNA
repair that was associated with elevated LV wall stress and activation of the inducible NO
synthase. (J Am Coll Cardiol 2002;40:1097–103) © 2002 by the American College of
Cardiology Foundation
Apoptosis is a cell death pathway whose role in human heart
failure is provocative but as yet unproven (1–6). Previous
studies reporting a wide range of apoptosis (1–6) were
performed in explanted end-stage failing hearts and based
on the terminal deoxynucleotidyltranseferase-mediated
biotin-dUTP nick-end labeling (TUNEL) technique to
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detect deoxyribonucleic acid (DNA) fragmentation as a
marker of apoptosis (5,6). However, the accuracy of this
technique can be confounded by living cells undergoing
ribonucleic acid (RNA) synthesis/splicing (7), active DNA
repair/proliferation (8–10), or by methodologic set-up (8–10).
Of note, several DNA repair enzymes determine the fate
of the cell after DNA damage either toward apoptosis
(11,12) or toward the repair of the damaged DNA (13–18).
Downregulation of the redox factor apurinic/apyrimidinic
endonuclease Ref-1-protein (APE/Ref-1) is consistent with
the DNA repair failure and was shown to coincide with
apoptosis in several cell types (11,12). The proliferative cell
nuclear antigen (PCNA) (13,14) and poly (adenosine
diphosphate-ribose) polymerase (PARP) (15,16) are other
proteins required for a successful nucleotide excision repair.
In addition, the catalytic subunit of the DNA-dependent
protein kinase (DNA-PKcs) is a key signaling protein
sensing the DNA damage and triggering the cascade of a
DNA double-strand repair (17,18). Repair of cardiac myo-
cytes could be an important defensive mechanism of the
failing heart to maintain normal left ventricular (LV) wall
stress by preserving the number of the myocytes. However,
the expression of these enzymes and their relationship with
hemodynamic phenotype in human heart failure is not
known. In addition, the inducible nitric oxide synthase
(iNOS) and its mediated oxidative stress have been postu-
lated to modulate LV contractile function in vivo. Never-
theless, the effects of iNOS on the nuclear repair or cell
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death are controversial (19–22). Therefore, this study tested
the hypothesis that the failing myocardium due to idio-
pathic dilated cardiomyopathy undergoes active DNA re-
pair and that this reparative process is related to both
hemodynamic and nitric oxide-mediated stress.
METHODS
Patients. Twenty-six patients undergoing left and right
heart catheterization and LV biopsy due to idiopathic
dilated cardiomyopathy were selected. No patient had sig-
nificant coronary artery diseases as documented by angiog-
raphy. All patients received standard heart failure medica-
tion including diuretics and angiotensin-converting enzyme
inhibitors. Only three patients received beta-blockers prior
to catheterization. None of the patients received inotropic
or other intravenous therapy. In addition, none of the
patients underwent any other invasive procedure or suffered
from the surinfection prior to catheterization. The biopsies
were fixed in 4% paraformaldehyde for further analyses. Of
the total number of biopsies, two were too small to be
analyzed, and in one biopsy several stainings failed, presum-
ably due to insufficient fixation. The study protocol was
approved by the local ethical committee.
TUNEL labeling. The TUNEL labeling was performed
using “the stringent approach” without pretreatment with
proteinase K as previously described (7–9). Negative con-
trols included omission of terminal deoxynucleotidyl trans-
ferase (TdT) from the labeling mixture. Tonsils were used
as positive controls.
Immunohistochemistry. To analyze the degree of intersti-
tial inflammation, the leukocytes in the interstitial regions
were detected using the CD34 antibody (concentration
1/400, Dako, Copenhagen, Denmark). To estimate the
extent of fibrosis in the LV biopsies a trichrome-Masson
staining was used. To detect the cleavage of proteins during
apoptosis, the biopsies were stained with anti-cleaved
caspase-3 antibody (concentration 1/200) and cleaved
PARP antibody (concentration 1/750, Pharmingen, San
Diego, California). To investigate the proteins involved in
the DNA repair/synthesis, specimens were stained with
antibodies against PARP (concentration 1/750), PCNA
(concentration 1/30, Dako, Copenhagen, Denmark), APE/
Ref-1 protein (concentration 1/400, Santa Cruz, CA), DNA-
PKcs (concentration 1/100, Neomarkers/Labovision), and
Ki67 (Dako). The iNOS antibody (concentration 1/2,500,
Biomol) was used to detect the iNOS protein. Finally,
8-oxo-deoxyguanosine staining (concentration 1/800, The
Japan Institute for the Control of Aging) was performed to
detect the presence of oxidative DNA damage. All primary
antibodies were detected by a peroxidase antibody conjugate
technique using either a goat anti-mouse peroxidase anti-
body (Jackson Laboratories) or rabbit anti-rat antibodies
(Dako, Copenhagen, Denmark). Tonsils and atherosclerotic
plaques were used as controls.
Histological quantification. The quantifications were per-
formed using a point-counting grid. The extent of fibrosis
was quantified using a point-counting grid from the entire
biopsy. The LV myocyte diameter was averaged from
myocytes sectioned perpendicular to the direction of the
nucleus. The extent of PCNA, DNA-PKcs, and APE/
Ref-1 protein-labeled myocytes was analyzed by a system-
atic random sampling as previously described (23,24) by
counting 500 to 750 cells in 15 fields. Among the total
number of cells, 250 to 300 myocytes were counted. The
extent of the CD34, iNOS, 8-oxo-deoxyguanosine, and
PARP staining was analyzed semiquantitatively on a 1-to-4
scale based on the number of stained cells and on the
intensity of the staining. All histological quantitative anal-
yses were performed by observers unaware of the hemody-
namic data.
Hemodynamic analysis. The left ventricular ejection frac-
tion (LVEF) was derived from the single-plane angiogram
using the area-length method. Patients were divided into
two groups according to their ejection fraction. Patients
with LVEF 35% were considered to have severe heart
failure. Both LV systolic and diastolic wall stress levels were
calculated using the combined echocardiographic and inva-
sive hemodynamic data (n  16).
Statistical analysis. All results are given as mean  SEM.
The Student t test, Fisher exact test, and Spearman correl-
lation coefficient and liner regression analyses were used for
appropriate comparisons. A p value of 0.05 was consid-
ered statistically significant.
RESULTS
Hemodynamics. Individual hemodynamic data and rela-
tive expression of DNA repair markers are shown in Table
1. Hemodynamic characteristics in both groups are shown
in Table 2. Patients with LVEF 35% had larger LV
volumes, higher LV end-diastolic pressure, and higher LV
systolic and diastolic wall stress as compared to patients with
LVEF35%. In addition, LV developed pressure tended to
be lower in patients with low LVEF.
Morphological analysis. Patients with LVEF 35% had
larger extent of interstitial fibrosis (23.8  5.5% vs. 7.6 
Abbreviations and Acronyms
APE/Ref-1  redox factor apurinic/apyrimidine
endonuclease Ref-1 protein
DNA  deoxyribonucleic acid
DNA-PKcs  deoxyribonucleic acid-protein kinase
catalytic subunit
iNOS  inducible nitric oxide synthase
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
PARP  poly (adenosine diphosphate-ribose)
polymerase
PCNA  proliferative cell nuclear antigen
RNA  ribonucleic acid
TUNEL  terminal deoxynucleotidyltranseferase-
medaited biotin-dUTP nick-end labeling
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1.7%, p  0.01) and higher incidence of CD34-positive
cells (63% [10/16] vs. 25% [2/8], p  0.05) as compared to
patients with LVEF35%. Both groups had similar degree
of cellular hypertrophy as assessed by the LV short-axis
diameter (28.6  1.4 m vs. 25.6  1.8 m, p  NS).
TUNEL labeling. In this study, no positive TUNEL
labeling could be detected in any patient regardless of the
degree of LV dysfunction (Fig. 1). In addition, no positive
staining for cleaved PARP or cleaved caspase-3 in the LV
biopsies of any patient could be detected. These observa-
tions argue against the presence of apoptosis in our patients
with idiopathic cardiomyopathy.
DNA repair enzymes. Figure 2 and Table 3 show the
percentage of the cardiac myocytes expressing the DNA
repair/synthesis enzymes. The APE/Ref-1 protein was
found in all patients, and the number of Ref-1 protein-
positive myocytes tended to be higher in patients with
LVEF 35% as compared to patients with LVEF 35%.
In addition, the incidence of the PARP expression was
similar in patients with LVEF 35% as compared to
patients with LVEF35% (99% [7/8] vs. 67% [10/15], p
NS). Second, positive PCNA staining was observed in 3
patients (37%) with LVEF 35% and in 10 patients (67%)
with LVEF 35% (p  NS). The number of PCNA-
positive myocytes was higher in patients with LVEF35%.
Finally, the expression of DNA-PKcs was found in 4
patients with LVEF 35% (50%) and in 14 patients with
LVEF 35% (93%, p  0.05). The number of the
DNA-PKcs-positive cardiac myocytes was higher in pa-
tients with LVEF 35% as compared to patients with
LVEF 35%. Furthermore, a weak but significant correla-
tion was observed between the DNA-PKcs and PCNA (r
0.54, p  0.008) and APE/Ref-1 protein expression (r 
0.43, p  0.04).
To investigate whether activation of the PCNA and
DNA-PKcs proteins is associated with the cell proliferation,
LV endomyocardial biopsies were stained for the Ki-67
protein, a marker of DNA replication. No biopsy specimen
stained positive for this protein, suggesting that the PCNA
activation was due to the DNA repair.
Hemodynamic and humoral correlates of the nuclear
repair. Figure 3 shows the correlation between the hemo-
dynamic indices and myocardial DNA-PKcs. A significant
relationship was found between the LV systolic wall stress
and expression of the PCNA, APE/Ref-1 protein, and
DNA-PKcs. Furthermore, a significant inverse relationship
Table 2. Hemodynamics
LVEF >35%
(n  8)
LVEF <35%
(n  15)
LVEF (%) 51  5 25  7*
LV EDVI (ml/m2) 77  28 130  52*
LV ESVI (ml/m2) 29  10 86  36*
LV devP (mm Hg) 130  31 112  25
LV EDP (mm Hg) 16  6 22  7*
LV systolic wall stress (kdyn/cm2) 112  20 194  54*
LV diastolic wall stress (kdyn/cm2) 28  16 46  18*
*p  0.01 vs. LVEF 35%.
LV left ventricular; LV EDVI left ventricular end-diastolic volume index; LV
ESVI  left ventricular end-systolic volume index; Other abbreviations as in Table 1.
Table 1. Individual Patient Characteristics
Patient
# Gender
Age
(yrs)
LVEF
(%)
LV devP
(mm Hg)
LV EDP
(mm Hg)
PCNA
(%)
DNA-PK
(%)
APE/Ref-1
(%)
1 F 35 57 133 16 0 0 4.87
2 M 51 57 173 18 0 31.43 26.83
3 M 45 54 111 7 4.61 0 40.74
4 F 69 52 82 18 2.54 0.54 1.17
5 F 64 51 174 14 0 36.21 30.95
6 F 55 49 110 22 0 0 3.95
7 F 64 45 126 24 0 0 1.09
8 M 59 43 134 6 0.14 0.79 0.71
9 F 65 35 124 26 1.81 41.30 12.35
10 M 49 35 88 22 0 36.21 3.61
11 M 46 33 121 9 33.05 77.27 19.51
12 F 29 28 142 27 3.37 48.56 38.18
13 M 57 26 123 27 25.81 39.47 73.07
14 M 56 23 124 10 0 21.62 1.32
15 M 48 22 80 22 0 57.89 13.69
16 M 38 22 126 12 0 14.81 8.33
17 F 48 20 115 24 4.87 44.44 22.78
18 F 43 18 84 28 0 0 5.31
19 M 66 18 83 17 0 58.33 16.67
20 M 57 36 109 23 8.91 29.87 34.41
21 M 45 23 138 22 2.78 48.67 21.12
22 M 59 13 93 30 24.71 61.24 48.05
23 M 58 28 94 27 1.79 12.18 20.63
APE/Ref-1 redox factor apurinic/apyrimidine endonuclease Ref-1 protein; DNA-PK deoxyribonucleic acid-protein kinase;
LVEF  left ventricular ejection fraction; LV devP  left ventricular developed pressure; LV EDP  left ventricular
end-diastolic pressure; PCNA  proliferative cell nuclear antigen.
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was observed between the number of DNA-PKcs-positive
myocytes and LVEF (r  0.53, p  0.003). Finally, the
number of DNA-PKcs-positive myocytes correlated signif-
icantly with both LV end-diastolic and end-systolic volume
indices (r  0.59, p  0.008, and r  0.57, p  0.01).
To investigate whether the DNA repair process is asso-
ciated with the oxidative DNA damage, LV biopsies were
analyzed for the iNOS and 8-oxo-deoxyguanosine. The
expression of DNA-PKcs and PCNA correlated signifi-
cantly with the iNOS expression in the cardiac myocytes
(r  0.53, p  0.02, and r  0.41, p  0.05, respectively).
As shown in Figure 4, there was a good concordance in the
iNOS expression and the DNA-PKcs expression in the
entire study population and in patients with LVEF 35%.
Of note, 8-oxo-deoxyguanosine, a marker of oxidative DNA
damage, was found in 62% (5/8) of patients with LVEF35%
and in 73% (11/15) of patients with LVEF 35% (NS).
Furthermore, the Ref-1 protein and PCNA expression corre-
lated significantly with 8-oxo-deoxyguanosine expression (r 
0.64, p  0.01, and r  0.48, p  0.02).
DISCUSSION
The results of our study show that: 1) cardiac myocytes of
patients with LV dysfunction do not show TUNEL-
positive labeling or cleavage of proteins during the process
of apoptosis regardless of the severity of heart failure; and 2)
in contrast, idiopathic cardiomyopathy is associated with
active DNA repair that appears to be associated with
elevated LV wall stress and activated iNOS.
Apoptosis in human heart failure. The prevalence of
apoptosis in patients with end-stage heart failure varies
widely (1–6). In contrast to previous studies (1–6), we did
not observe TUNEL-positive labeling or other apoptotic
markers such as cleaved caspase-3 or cleaved PARP in any
LV endomyocardial specimen either in severe or mild LV
dysfunction. Our data are consistent with Kanoh et al. (10),
who despite positive TUNEL staining also failed to observe
other morphological markers of apoptosis in patients with
dilated cardiomyopathy. Likewise, other studies reported
lower or no incidence of positive TUNEL staining in
end-stage myopathies (3,4,9).
A sharp difference in the prevalence of apoptosis may be
due to several reasons. First, previous studies (4,5) uniformly
included patients with end-stage heart failure, and detection
of apoptosis was performed in explanted hearts. In contrast,
we investigated LV endomyocardial biopsies obtained in
vivo and studied patients with a wide range of LV dysfunc-
tion. Second, previous studies utilized conventional
TUNEL assay with proteinase K pretreatment. This may
cause interference with the RNA synthesis or DNA repair
in the living cells (7). To avoid such false positive labeling,
we utilized a “stringent” TUNEL technique without pre-
treatment with proteinase K that avoids a specific binding
due to DNA repair or necrosis (7–9).
DNA repair in human heart failure. In contrast to cell
death, several findings in our study suggest that failing
cardiac myocytes were undergoing active DNA repair. First,
the expression of the APE/Ref-1 protein was preserved in
Figure 1. An example of “stringent” TUNEL without the use of proteinase K in positive control (tonsil panel A, 1000) and in a patient with dilated
cardiomyopathy (panel B, 200). Arrows indicate the presence of TUNEL-positive nuclei in tonsils. Note that when utilizing the “stringent” approach,
no TUNEL-positive labeling has been observed in dilated cardiomyopathy patients.
Figure 2. An example of staining for the deoxyribonucleic acid-protein kinase catalytic subunit (A), proliferative cell nuclear antigen (B), and
apurinic/apyrimidine endonuclease/redox factor 1 (C) from a patient with left ventricular ejection fraction 35% (1000 magnification).
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all patients. This DNA enzyme is responsible for preserving
the genomic stability by repairing the apurinic/apyrimidinic
sites, and its downregulation appears to precede the cell
death during the neuronal apoptosis (11,12). Our data
corroborate the hypothesis that the preserved expression of
this base excision-repair enzyme in advanced heart failure
may be crucial to prevent apoptosis in nonischemic cardio-
myopathy. Second, the expression of the PCNA protein, a
co-factor of DNA polymerase required for DNA synthesis
(13,14), was higher in patients with severe LV dysfunction.
Third, the DNA-PKcs is a crucial component of the DNA
double-strand break-repair machinery that recognizes DNA
damage and recruits the DNA repair machinery (17,18,25).
Of note, the enzyme is upregulated during the cell division
(26) or during nonhomologous recombination and repair
(27). In this study, we report a novel observation of
upregulation of the DNA-PKcs in cardiac myocytes of the
failing myocardium. Because no LV biopsy specimen
showed the expression of the Ki-67 protein (28), the
activation of both PCNA and DNA-PKcs in the failing
myocytes corroborates the presence of active nuclear exci-
sion repair rather than DNA replication (10). Finally, none
of the LV endomyocardial specimen showed the cleaved
form of PARP. In contrast, the PARP protein was detected
in the majority of the patients with severe LV dysfunction.
Thus, these data indicate that the failing human myocar-
dium due to idiopathic dilated cardiomyopathy is associated
with DNA damage. Moreover, our observations support the
hypothesis that, in response to the DNA damage, failing
cardiac myocytes primarily recruit factors aimed for cell
survival rather than for cell death.
Hemodynamic and humoral factors associated with
DNA damage/repair. The factors and mechanisms asso-
ciated with the DNA damage/repair in human heart failure
are not entirely clear. Our observation of upregulated
DNA-PKcs and other DNA repair enzymes in patients
with elevated LV wall stress suggests that pure mechanical
load is sufficient to trigger the DNA damage/repair process.
This corroborates earlier in vitro observations of a direct
myocyte damage in response to acute mechanical stretch
(29). However, in contrast to this study, the failure to
observe markers of apoptosis in our study suggests that the
cellular response to the mechanical load in vivo is complex
and may depend on the local environment.
In this regard, recent experimental study indicated that
pacing-induced heart failure is associated with increased
levels of nitrotyrosine and oxidative stress that shift the
balance from DNA repair toward apoptosis with loss of
DNA-PKcs expression (22). In our study, 8-oxo-
deoxyguanosine, a marker of oxidative DNA damage, was
detected in the cardiac myocytes of the majority of patients,
even those with severe LV dysfunction. However, in con-
trast to the latter experimental study, all patients but one
stained positive for DNA-PKcs. In addition, the marker of
Table 3. DNA Repair Enzymes
LVEF >35%
(n  8)
LVEF <35%
(n  15)
APE/Ref-1-positive myocytes (%) 13.8  5.7 21.2  4.8
PCNA-positive myocytes (%) 0.9  1.6 7.1  2.8*
DNA-PKcs-positive myocytes (%) 8.6  5.5 39.5  5.4*
*p  0.05 vs. LVEF 35%.
APE/Ref-1  the redox factor/apurinic/apyrimidine endonuclease Ref-1 protein;
DNA-PKcs  catalytic subunit of the DNA protein kinase; LVEF  left ventricular
ejection fraction; PCNA  proliferating cell nuclear antigen.
Figure 3. Relationship between the proliferative cell nuclear antigen (PCNA), apurinic/apyrimidine endonuclease/redox factor 1 (APE/Ref-1), and
deoxyribonucleic acid-protein kinase catalytic subunit (DNA-PKcs) expression and left ventricular (LV) systolic wall stress.
Figure 4. Relationship between the deoxyribonucleic acid-protein kinase
catalytic subunit (DNA-PKcs) and inducible nitric oxide synthase (iNOS)
expressions in all patients and in patients with left ventricular ejection
fraction (LVEF) 35%.
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oxidative nuclear damage correlated with other DNA repair
proteins. This suggests that, in the failing myocardium, even
a high degree of oxidative DNA damage is followed
primarily by increased DNA repair activity, and apoptosis
occurs only after defensive mechanisms fail (30).
Of note, previous studies suggested that iNOS-mediated
signaling may play a dual role in cellular defensive mechanisms.
On the one hand, in vitro studies demonstrated that
iNOS-mediated oxidative stress is an important regulator of
apoptosis (19,20). On the other hand, it has been also
shown that NO-mediated signaling may inhibit caspase
activity (21). In addition, a recent study indicated that NO
interacts with the DNA repair machinery by activating the
DNA-PKcs (31). In the present study, we observed positive
iNOS staining in the majority of patients with advanced
heart failure, and, yet, no activation of caspases was seen. In
contrast, the presence of iNOS activation coincided with
the expression of markers of DNA repair enzymes such as
PCNA and DNA-PKcs in patients with severely depressed
LV function. Thus, our observations corroborate the hy-
pothesis that local cardiac excessive NO generation in vivo
does not inevitably cause cell death. Conversely, it can
promote the DNA repair/survival machinery by the mech-
anisms that are not entirely clear from the present study.
Taken together, these data suggest that DNA damage in the
failing myocardium results from a direct hemodynamic
stress where humoral factors are likely to play a modulatory
role.
Study limitations. First, LV endomyocardial biopsies
though taken in vivo represent only a small part of the LV,
and absence of apoptotic markers in the biopsy does not
exclude the possibility of apoptosis in other parts of the LV.
Second, apoptosis and repair are dynamic processes, and
one-time analysis may underestimate the incidence of apo-
ptosis or repair. Furthermore, apoptosis was assessed using
only the “stringent” TUNEL technique and from the
cleavege of caspase-3 and PARP, and no other techniques
such as Taq polymerase assay or electromicroscopy were
performed to detect apoptotic cell death. In addition, we did
not perform other RNA or protein lysate analyses to
quantitate the expression of DNA repair enzymes in the LV
endomyocardial biopsies. Finally, we studied only patients
with dilated cardiomyopathy, and thus our results cannot be
extended to other models of LV dysfunction. In particular,
previous studies demonstrated that ischemia and ischemia/
reperfusion injury are potential apoptotic stimuli (32,33).
Moreover, in the pressure-overload hypertrophy model
(34,35), the presence of apoptosis coincides with the tran-
sition from compensated hypertrophy to heart failure.
Conclusions. The present study supports the hypothesis
that, in nonischemic dilated cardiomyopathy, the incidence
of apoptosis is low and does not substantially contribute to
the progression of disease. In contrast, advanced heart
failure is associated with the activation of DNA repair
proteins. This appears to be associated with elevated LV
wall stress and iNOS. Further studies are required to
investigate the mechanisms contributing to the induction of
nuclear reparative processes rather than to mechanisms
contributing to cell death.
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